Burixafor (hydrobromide)
Burixafor (TG-0054) hydrobromide is a selective, orally active CXCR4 antagonist that effectively blocks the interaction between CXCR4 and its ligand, stromal cell-derived factor SDF-1. Burixafor hydrobromide interferes with the SDF-1/CXCR4 signaling pathway, prompting the release of bone marrow stem cells into the peripheral circulation, exerting immunomodulatory and anti-inflammatory activities. Burixafor hydrobromide can be used in the study of cancer, Intraocular neovascular diseases (such as choroidal neovascularization), myocardial infarction and other diseases, with the potential to mobilize stem cells, improve cardiac function and reduce inflammatory responses[1][2][3].
Product Specifications
CAS Number
1191450-19-7
Product Name Alternative
TG-0054 (hydrobromide)
UNSPSC
12352005
Target
CXCR; VEGFR
Type
Reference compound
Related Pathways
GPCR/G Protein; Immunology/Inflammation; Protein Tyrosine Kinase/RTK
Applications
COVID-19-immunoregulation
Field of Research
Cancer; Endocrinology; Inflammation/Immunology; Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/Burixafor_hydrobromide.html
Purity
98.0
Solubility
H2O : 50 mg/mL (ultrasonic)
Smiles
NC1=CC(N2CCN(CCP(O)(O)=O)CC2)=NC(NC[C@H]3CC[C@H](CNCCCNC4CCCCC4)CC3)=N1.[H]Br
Molecular Formula
C27H51N8O3P.5/2HBr
Molecular Weight
769.01
References & Citations
Shipping Conditions
Blue Ice
Storage Conditions
-20°C (Powder, stored under nitrogen)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
CXCR4
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Ep-CAM / CD326 (Extracellular Domain) (Epithelial Marker) (EGP40/1384), CF640R conjugate, 0.1mg/mL
Fibronectin (Fn-3), CF647 conjugate, 0.1mg/mL
